Latest Regulatory News

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

5E Advanced Materials has successfully closed an oversubscribed US$36 million public offering, positioning itself to advance its boron operations and finalise key commercial contracts.

Diablo Resources has significantly increased its Star Range critical minerals project footprint in Utah, securing additional claims that extend the high-grade North Star Prospect. The move sets the stage for imminent drilling and advances the company’s alignment with US critical minerals supply goals.

Terrain Minerals has initiated diamond drilling at its Smokebush Gold & Silver Project, advancing toward a maiden JORC Mineral Resource estimate targeted for mid-2026. The company’s exploration momentum continues with ongoing RC drilling at Lightning and upcoming programs at Wildflower.

Pinnacle Investment Management reported an 11% drop in net profit after tax for the first half of FY26, despite record net inflows and a strategic move to fully acquire Pacific Asset Management.

The Federal Court of Australia has approved the acquisition schemes for Global Uranium and Enrichment Limited by Snow Lake Resources, setting the stage for a significant shift in shareholder structure and market listing.

Ryman Healthcare has unveiled a refreshed strategy focused on growing recurring earnings and optimising its portfolio, targeting a $150 million sustainable cash flow improvement and $500 million cash release by FY29. The company plans to resume dividends from FY28, underpinned by a resilient balance sheet and disciplined capital management.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

Verity Resources is raising approximately $2 million through a non-renounceable entitlement offer to advance its Monument Gold and Botswana copper-silver projects, with directors backing the move through participation and underwriting.

Little Green Pharma Ltd is set to acquire Cannatrek Ltd in a transformative merger that will create one of the largest vertically integrated medicinal cannabis companies globally, with pro-forma FY25 revenue exceeding AUD 112 million.